Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients
Open Access
- 1 June 2004
- Vol. 90 (6) , 638-644
- https://doi.org/10.1136/hrt.2003.017509
Abstract
Objective: To evaluate symptomatic and haemodynamic results of transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy in elderly patients. Setting: Tertiary referral centre for patients with hypertrophic obstructive cardiomyopathy. Design: Retrospective study of two groups of consecutive patients divided at a median age (59 years). Patients: Transcoronary ablation of septal hypertrophy was compared for 80 patients (group 1) < 60 years of age and 77 patients (group 2) ⩾ 60 years of age. At baseline both groups were similar concerning the proportion of familial hypertrophic cardiomyopathy, concomitant moderate hypertension, prior syncope, left ventricular outflow obstruction, left ventricular end diastolic pressure, and left ventricular ejection fraction. Patients in group 2 had a lower interventricular septal thickness and more severe disease as measured by New York Heart Association (NYHA) functional class, exercise capacity, pulmonary artery mean pressure at workload, and cardiac index at peak exercise. Results: Median follow up was seven months after transcoronary ablation of septal hypertrophy. Both groups had a significant and similar improvement in basal and provokable obstruction, septal thickness, NYHA functional class, exercise tolerance, peak oxygen consumption, and pulmonary artery mean pressure at workload. Significant differences, compared with the younger group, were a higher proportion of persistent total atrioventricular block (5% v 17%, p = 0.015) and a slight decrease in left ventricular ejection fraction (3 (12) v −6 (11)%, p = 0.001) in the elderly, despite a trend to a lower induced peak creatine kinase activity (596 (339) v 491 (331) U/l, p = 0.051). Conclusions: Short term results with transcoronary ablation of septal hypertrophy suggest that independent of a patient’s age similar treatment strategies are justified in hypertrophic obstructive cardiomyopathy.Keywords
This publication has 40 references indexed in Scilit:
- To ablate or operate? that is the question!**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.Journal of the American College of Cardiology, 2001
- EditorialJournal of the American College of Cardiology, 1998
- Comparison of clinical features in patients ≥60 years of age to those ≤40 years of age with hypertrophic cardiomyopathyThe American Journal of Cardiology, 1990
- Elderly patients with hypertrophic cardiomyopathy: A subset with distinctive left ventricular morphology and progressive clinical course late in lifeJournal of the American College of Cardiology, 1989
- Age-Related Changes in Normal Human Hearts During the First 10 Decades of Life. Part II (Maturity): A Quantitative Anatomic Study of 765 Specimens From Subjects 20 to 99 Years OldMayo Clinic Proceedings, 1988
- Hypertrophic CardiomyopathyNew England Journal of Medicine, 1987
- Hypertensive Hypertrophic Cardiomyopathy of the ElderlyNew England Journal of Medicine, 1985
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978
- Hypertrophic cardiomyopathy in the agedAmerican Heart Journal, 1978
- Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients.Circulation, 1975